Three visits. 8 weeks.
A new cutting edge allergy shot treatment: only 1–2 targeted injections per session, completed in just three visits.
Learn about RapImmune™ in more detail.
THE SCHEDULE IS THE FRICTION
Allergy shots and sublingual drops are established options. The challenge is the commitment: 100+ injections over 3–5 years, weekly visits during build-up, or daily drops for years. RapImmune™ focuses on a shorter treatment path without claiming a superior outcome.
Small doses of allergen extract are placed into a lymph node using ultrasound guidance. The procedure is typically described as blood-draw-level discomfort, followed by a 30-minute observation window before returning to the day.
FDA disclosure: the allergen extracts used are FDA-approved. The intralymphatic injection method itself is not yet FDA-approved.
A QUICK SELF-CHECK
Ongoing environmental allergens: pollen, dust mites, pets, or molds.
Other treatment options have already been considered or tried.
Weekly appointments or daily routines are difficult to sustain.
A simpler path with fewer steps is a priority.
Intralymphatic immunotherapy was studied in the 2008 Zurich trials led by Dr. Gabriela Senti. More than 15 years of European and U.S. research have followed, including work at Ohio State. Allergenix is Iowa’s first clinic to offer this protocol. The clinical evidence, expected outcomes, and limitations are reviewed during the candidacy discussion.
A SIMPLER COMPARISON
How does cost and insurance work?
Allergenix uses a Direct Specialty Care model. The clinic does not bill insurance or seek prior authorizations; pricing is shared directly before care begins.
What happens after the 8 weeks?
The next step is individualized. Follow-up and any clinically indicated booster planning are discussed with the treating team.
Who administers RapImmune™?
RapImmune™ is physician-guided at Allergenix by Sean Stanga, M.D.
Is the treatment safe?
Safety, candidacy, and the current evidence are reviewed in detail before treatment. Allergen extracts are FDA-approved; the intralymphatic injection method itself is not yet FDA-approved.
A brief first step for deciding whether RapImmune™ belongs in the next treatment conversation.